Biomarker discovery and clinical proteomics
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis). Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity and specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue. Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
OBESE, A NEW MUTATION IN THE HOUSE MOUSE*
INGALLS, A. M., DICKIE, M. M., & SNELL, G. D. (1950) · Journal of Heredity · doi:10.1093/oxfordjournals.jhered.a106073 · Cited by 1,090
Dynorphin-(1-13), an extraordinarily potent opioid peptide.
Goldstein, A., Tachibana, S., Lowney, L. I., Hunkapiller, M., & Hood, L. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.12.6666 · Cited by 882
Pieper, R., Su, Q., Gatlin, C. L., Huang, S., Anderson, N. L., & Steiner, S. (2003) · PROTEOMICS · doi:10.1002/pmic.200390057 · Cited by 356
A HUPO test sample study reveals common problems in mass spectrometry–based proteomics
HUPO Test Sample Working Group, Bell, A. W., Deutsch, E. W., Au, C. E., Kearney, R. E., Beavis, R., Sechi, S., Nilsson, T., & Bergeron, J. J. M. (2009) · Nature Methods · doi:10.1038/nmeth.1333 · Cited by 351
Next-generation high-density self-assembling functional protein arrays
Ramachandran, N., Raphael, J. V., Hainsworth, E., Demirkan, G., Fuentes, M. G., Rolfs, A., Hu, Y., & LaBaer, J. (2008) · Nature Methods · doi:10.1038/nmeth.1210 · Cited by 303
Yan, L., Tonack, S., Smith, R., Dodd, S., Jenkins, R. E., Kitteringham, N., Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2009) · Journal of Proteome Research · doi:10.1021/pr800451h · Cited by 44
Cited by
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
“Despite great promise for MS in clinical proteomics, many challenges remain including issues of sensitivity (typically nM in current approaches), specificity, reproducibility, throughput, and cost [2–9].”
BackgroundSalivary Biomarkers: Toward Future Clinical and Diagnostic Utilities
Yoshizawa, J. M., Schafer, C. A., Schafer, J. J., Farrell, J. J., Paster, B. J., & Wong, D. T. W. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-13 · Cited by 656
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Füzéry, A. K., Levin, J., Chan, M. M., & Chan, D. W. (2013) · Clinical Proteomics · doi:10.1186/1559-0275-10-13 · Cited by 428
Ahmad, A., Imran, M., & Ahsan, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061630 · Cited by 386
Saliva: A potential media for disease diagnostics and monitoring
Liu, J., & Duan, Y. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.01.021 · Cited by 308
Metadata
- Authors
- Silberring, J., & Ciborowski, P.
- Venue
- TrAC Trends in Analytical Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 29
- Issue
- 2
- Pages
- 128-140
- ISSN
- 0165-9936 (ISSN-L)
- OpenAlex
- W2053712992
- Cited by
- 101
- References
- 8
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.